[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HRPK20050567B3 - Perindopril - Google Patents

Perindopril

Info

Publication number
HRPK20050567B3
HRPK20050567B3 HR20050567A HRP20050567A HRPK20050567B3 HR PK20050567 B3 HRPK20050567 B3 HR PK20050567B3 HR 20050567 A HR20050567 A HR 20050567A HR P20050567 A HRP20050567 A HR P20050567A HR PK20050567 B3 HRPK20050567 B3 HR PK20050567B3
Authority
HR
Croatia
Prior art keywords
perindopril
reciprocal
integers
integer
formula
Prior art date
Application number
HR20050567A
Other languages
English (en)
Croatian (hr)
Inventor
Ramachandra Rao Dharmaraj
Narayanrao Kankan Rajendra
Original Assignee
Cipla Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cipla Ltd filed Critical Cipla Ltd
Publication of HRP20050567A2 publication Critical patent/HRP20050567A2/hr
Publication of HRPK20050567B3 publication Critical patent/HRPK20050567B3/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Catalysts (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HR20050567A 2002-11-18 2005-06-17 Perindopril HRPK20050567B3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0226885A GB2395195A (en) 2002-11-18 2002-11-18 Preparation of perindopril from carboxy-protected precursor, & perindopril monohydrates for use as angiotensin converting enzyme (ACE) inhibitors
PCT/GB2003/004981 WO2004046172A1 (en) 2002-11-18 2003-11-18 Perindopril

Publications (2)

Publication Number Publication Date
HRP20050567A2 HRP20050567A2 (hr) 2005-12-31
HRPK20050567B3 true HRPK20050567B3 (en) 2007-08-31

Family

ID=9948057

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20050567A HRPK20050567B3 (en) 2002-11-18 2005-06-17 Perindopril

Country Status (28)

Country Link
US (1) US7351840B2 (de)
EP (2) EP1565485B1 (de)
JP (2) JP5110770B2 (de)
KR (1) KR20050075429A (de)
CN (2) CN1966519A (de)
AT (2) ATE352555T1 (de)
AU (2) AU2003283588B2 (de)
BR (1) BR0315703A (de)
CA (1) CA2506587A1 (de)
DE (2) DE60329722D1 (de)
DK (1) DK1565485T3 (de)
EC (1) ECSP055865A (de)
ES (2) ES2279188T3 (de)
GB (1) GB2395195A (de)
GE (1) GEP20105036B (de)
HR (1) HRPK20050567B3 (de)
IL (1) IL168660A (de)
IS (1) IS7893A (de)
MA (1) MA27567A1 (de)
MX (1) MXPA05005333A (de)
NZ (1) NZ540360A (de)
PL (1) PL376931A1 (de)
PT (2) PT1688427E (de)
RU (1) RU2339645C2 (de)
SI (1) SI1565485T1 (de)
TN (1) TNSN05140A1 (de)
WO (1) WO2004046172A1 (de)
ZA (1) ZA200503979B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2395195A (en) * 2002-11-18 2004-05-19 Cipla Ltd Preparation of perindopril from carboxy-protected precursor, & perindopril monohydrates for use as angiotensin converting enzyme (ACE) inhibitors
CN100395235C (zh) * 2003-06-24 2008-06-18 瑟维尔实验室 培哚普利特丁胺的新晶形
GB2413128A (en) * 2004-04-13 2005-10-19 Neopharma Ltd Process for the preparation of perindopril
SI21881A (sl) 2004-10-15 2006-04-30 Diagen, Smartno Pri Ljubljani, D.O.O. Nove kristalne oblike perindopril erbumin hidratov, postopek za njihovo pripravo in farmacevtske oblike, ki vsebujejo te spojine
WO2007017893A2 (en) * 2005-05-05 2007-02-15 Arch Pharmalabs Limited Preparation of novel crystalline form of perindopril erbumine monohydrate
AU2006278866B2 (en) * 2005-07-25 2012-03-15 Lek Pharmaceuticals D.D. Process for the preparation of crystalline perindopril
WO2007020012A1 (en) * 2005-08-12 2007-02-22 Lek Pharmaceuticals D.D. A process for the preparation of perindopril erbumine
CN101227902A (zh) * 2005-08-12 2008-07-23 桑多斯股份公司 培哚普利特丁胺的新结晶形式
DE102005058166A1 (de) * 2005-12-05 2007-06-06 Hexal Ag Matrixkontrolliertes transdermales System mit Amin-Salzen der ACE-Hemmer-Dicarbonsäuren
SI22543A (sl) 2007-06-27 2008-12-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Nove soli perindoprila
CN101332191B (zh) * 2008-07-10 2013-01-09 沈阳药科大学 一种稳定的培哚普利叔丁胺盐片剂及其制备方法
SI23149A (sl) 2009-09-21 2011-03-31 Silverstone Pharma Nove benzatinske soli ACE inhibitorjev, postopek za njihovo pripravo in njihova uporaba za zdravljenje kardiovaskularnih bolezni
ES2686298T3 (es) 2010-04-20 2018-10-17 Chiral Quest, Inc. Procedimiento enantioselectivo para alaninas beta sustituidas con cicloalquenilo
CN103110929A (zh) * 2012-12-10 2013-05-22 江苏开元医药化工有限公司 米屈肼和赖诺普利的药物组合物及其制备方法
CN105693817B (zh) 2014-11-27 2020-06-05 西北大学 一类三肽化合物及其制备方法与应用
WO2016178591A2 (en) 2015-05-05 2016-11-10 Gene Predit, Sa Genetic markers and treatment of male obesity
CN111116709B (zh) * 2019-12-31 2022-06-24 北京鑫开元医药科技有限公司 一种培哚普利制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2503155A2 (fr) * 1980-10-02 1982-10-08 Science Union & Cie Nouveaux imino diacides substitues, leurs procedes de preparation et leur emploi comme inhibiteur d'enzyme
US4508729A (en) * 1979-12-07 1985-04-02 Adir Substituted iminodiacids, their preparation and pharmaceutical compositions containing them
FR2620709B1 (fr) * 1987-09-17 1990-09-07 Adir Procede de synthese industrielle du perindopril et de ses principaux intermediaires de synthese
US6395300B1 (en) * 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
JP4018854B2 (ja) * 1999-10-28 2007-12-05 第一三共株式会社 抗悪性腫瘍薬
FR2807431B1 (fr) * 2000-04-06 2002-07-19 Adir Nouveau procede de synthese du perindopril et de ses sels pharmaceutiquement acceptables
FR2811319B1 (fr) 2000-07-06 2002-08-23 Adir Nouvelle forme cristalline beta du sel de tert-butylamine du perindopril, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2811320B1 (fr) 2000-07-06 2002-08-23 Adir Nouvelle forme cristalline alpha du sel de tert-butylamine du perindopril, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2811318B1 (fr) * 2000-07-06 2002-08-23 Adir Nouvelle forme cristalline gamma du sel de tert-butylamine du perindopril, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2838648B1 (fr) * 2002-04-18 2004-05-21 Servier Lab Nouveau sel de perindopril et les compositions pharmaceutiques qui le contiennent
GB2395195A (en) * 2002-11-18 2004-05-19 Cipla Ltd Preparation of perindopril from carboxy-protected precursor, & perindopril monohydrates for use as angiotensin converting enzyme (ACE) inhibitors
SI21881A (sl) * 2004-10-15 2006-04-30 Diagen, Smartno Pri Ljubljani, D.O.O. Nove kristalne oblike perindopril erbumin hidratov, postopek za njihovo pripravo in farmacevtske oblike, ki vsebujejo te spojine

Also Published As

Publication number Publication date
SI1565485T1 (sl) 2007-08-31
AU2003283588B2 (en) 2009-07-16
ES2279188T3 (es) 2007-08-16
DK1565485T3 (da) 2007-03-12
ZA200503979B (en) 2006-11-29
AU2003283588A1 (en) 2004-06-15
PT1565485E (pt) 2007-03-30
EP1565485B1 (de) 2007-01-24
US20060063941A1 (en) 2006-03-23
NZ540360A (en) 2007-12-21
AU2009202389B2 (en) 2012-03-29
GEP20105036B (en) 2010-07-12
BR0315703A (pt) 2005-10-25
MXPA05005333A (es) 2005-08-16
AU2009202389A1 (en) 2009-07-09
ES2333153T3 (es) 2010-02-17
JP5110770B2 (ja) 2012-12-26
EP1688427A1 (de) 2006-08-09
GB0226885D0 (en) 2002-12-24
RU2339645C2 (ru) 2008-11-27
EP1688427B1 (de) 2009-10-14
DE60329722D1 (de) 2009-11-26
ECSP055865A (es) 2005-11-22
GB2395195A (en) 2004-05-19
TNSN05140A1 (en) 2007-05-14
CN1738830A (zh) 2006-02-22
IS7893A (is) 2005-06-14
ATE445632T1 (de) 2009-10-15
WO2004046172A1 (en) 2004-06-03
KR20050075429A (ko) 2005-07-20
CN100371345C (zh) 2008-02-27
DE60311516D1 (en) 2007-03-15
ATE352555T1 (de) 2007-02-15
DE60311516T2 (de) 2007-10-25
PL376931A1 (pl) 2006-01-09
US7351840B2 (en) 2008-04-01
IL168660A (en) 2010-04-15
HRP20050567A2 (hr) 2005-12-31
RU2005119162A (ru) 2006-01-20
EP1565485A1 (de) 2005-08-24
JP2006520320A (ja) 2006-09-07
CN1966519A (zh) 2007-05-23
MA27567A1 (fr) 2005-10-03
CA2506587A1 (en) 2004-06-03
JP2013006839A (ja) 2013-01-10
PT1688427E (pt) 2009-11-06

Similar Documents

Publication Publication Date Title
DE60311516D1 (en) Perindopril
DE60336850D1 (en) Substituierte arylcyclopropylacetamide als glucokinaseaktivatoren
HK1069395A1 (en) Phthalazinone derivatives 2,3
AP2002002637A0 (en) Novel piperazine
IL159418A0 (en) Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
MXPA02003977A (es) Inhibidores de adhesion de celula mediada por al°2.
AU2001277753A1 (en) Phosphonocephem compound
YU82403A (sh) Jedinjenja spiropirazola
EP1420010A4 (de) Amphotere lipidverbindung und deren verwendung
YU30603A (sh) Derivati premošćenog piperazina
MXPA05006889A (es) Compuestos aromaticos como agentes anti-inflamatorios, inmunomoduladores y anti-proliferativos.
GB0218816D0 (en) Antitumoral analogs of lamellarins
MXPA05011521A (es) Derivado de 4,4-difluoro-1,2,3,4-tetrahidro-5h-1-benzazepina o una sal del mismo.
IL162788A (en) Process for preparing a tripeptide and salt thereof
MY139289A (en) Process for the synthesis of perindopril and pharmaceutically acceptable salts thereof
HK1083839A1 (en) Indoline compound and medicinal use thereof
GEP20094740B (en) Novel method for the synthesis of perindopril and the pharmaceutically acceptable salts thereof

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AKOB Publication of a request for the grant of a patent not including a substantive examination of a patent application (a consensual patent)
PKB1 Consensual patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20081117

Year of fee payment: 6

PBKO Lapse due to non-payment of renewal fee for consensual patent

Effective date: 20091119